BIG MONEY. PLAYING GOD. NO, REMOVING GOD, DENYING GOD, CLAIMING NO NEED OF GOD — TRANSFORMING ALL THAT HAS BEEN KNOWN. The power-mad anti-God, anti-Holy Bible pursuit of men and women. CRISPR. The noise of the Tower of Babel is alive and thriving as never before in world history.

Hurtling towards the end. Faster and faster each passing day.

The Strong Delusion grows deeper, stronger, darker, foolishly imagining it is light and redeeming and going to save.

It’s all about BIG MONEY. NOT PLAYING GOD — REPLACING GOD, DENYING GOD. TRANSHUMANISM, TRANSFORMING ALL THAT HAS BEEN KNOWN.

Not shouting. Emphasizing [the only reason I use caps unless grammatically correct; to emphasize] since most lie idle, deaf, blind, otherwise occupied, unbelieving — even those, many of those professing belief.

There are related links following the main article below, and a slanted, biased article about CRISPR following the RELATED links.

Read on…

Ken Pullen, Monday, May 19th, 2025

Gene Spliced and Spiritually Seduced

A Time of Genetic Corruption Is Here: Just Like The Days Of Noah

May 14, 2025

By Joe Hawkins

Reprinted from Prophecy Recon — Stay Awake Keep Watch

In Genesis 6, we read of a strange and disturbing time when “the sons of God came in to the daughters of men, and they bore children to them” (Genesis 6:4). These children were the Nephilim, mysterious hybrid beings who were “mighty men… men of renown.” While scholars debate the exact identity of the “sons of God,” my view is that they were fallen angels who transgressed their boundaries, resulting in a corrupted human race.

Jesus offered a chilling comparison in Matthew 24:37: “For the coming of the Son of Man will be just like the days of Noah.” This comparison begs a sobering question: If the world before the flood was marked by genetic corruption and hybrid entities, could we be heading toward a similar scenario today?

With CRISPR-Cas9, synthetic biology, and other advanced genetic engineering technologies at our fingertips, we are now able to manipulate DNA in ways unimaginable just decades ago. While these breakthroughs offer promising medical benefits, they also raise profound moral and theological concerns—especially when viewed through a prophetic lens.

The Days of Noah: A Time of Genetic Corruption

Genesis 6 describes not only extreme violence and wickedness, but also a profound corruption of human flesh:

“Then the LORD saw that the wickedness of man was great on the earth… and God looked on the earth, and behold, it was corrupt; for humanity had corrupted its way upon the earth” (Genesis 6:5, 12).

The Book of Enoch—though not canonical—shed more light on this corruption, describing how fallen angels taught humans forbidden knowledge, including weaponry, enchantments, astrology, and the manipulation of genetics. According to Enoch 7:2, the offspring of these unions were giants who “consumed all the acquisitions of men,” unleashing destruction upon the earth.

The flood wasn’t just about cleansing moral wickedness. It was also about preserving the integrity of God’s creation, especially the human genome. Noah is described as “blameless in his generations” (Genesis 6:9)—a phrase many believe refers to his uncontaminated lineage, not merely his moral character.

Jesus’ Warning: A Prophetic Parallel

When Jesus likens the Last Days to the “days of Noah,” He isn’t merely pointing to general wickedness or moral decay—though those are certainly present. He is referencing a time of spiritual and genetic rebellion, when boundaries between human and non-human were blurred.

Consider what we see today:

Genetically modified embryos are being created and destroyed in laboratories.

Human-animal chimeras are being developed for organ harvesting.

Gene-editing technologies are being used to “enhance” human traits—raising the specter of designer babies, super soldiers, and possibly even post-human entities.

These developments raise a critical question: Are we opening a door once sealed by God after the flood? If the Nephilim were a product of angelic-human hybridization in Genesis 6, then our modern scientific pursuits may be ushering in a return of those hybrid beings—not through supernatural union, but through technological sorcery.

CRISPR and the Modern Tower of Babel

CRISPR-Cas9 is a gene-editing tool that allows scientists to cut and paste sections of DNA with extreme precision. While originally hailed as a cure for genetic diseases, CRISPR has quickly expanded into areas of genetic enhancement and embryonic modification. In 2018, Chinese scientist He Jiankui shocked the world by announcing the birth of the first CRISPR-edited babies, sparking an international outcry.

The Tower of Babel (Genesis 11) represents another moment when humanity attempted to transcend God-ordained boundaries. They sought to “make a name for ourselves” and reach the heavens through their own ingenuity. God responded by scattering them and confusing their languages. Today, mankind is once again reaching for godlike powers—this time not through bricks and towers, but through genes and machines.

“There is nothing that they purpose to do will be impossible for them” (Genesis 11:6b).

This verse takes on new meaning in the age of synthetic biology, where scientists talk openly about “playing God” and “creating life” in the lab. Like the men of Babel, we are seeking immortality and dominion without the Creator.

Hybrid Beings and Transhumanism: Echoes of the Nephilim?

The Nephilim were hybrids—part divine, part human. Today’s scientists envision a future of transhumans: beings who are part human, part machine, or genetically enhanced beyond what God intended. The transhumanist movement openly advocates for the next step in evolution—a post-human future where our biology is no longer a limitation but a canvas for re-creation.

Even secular voices are alarmed. Elon Musk has warned of the dangers of AI-human symbiosis, and Yuval Noah Harari has famously described humans as “hackable animals.” In his worldview, free will is an illusion and the future belongs to those who control the genome and the algorithm.

Could it be that we are re-creating the very conditions that led to the flood? Could hybrid beings return, not through angelic rebellion, but through technological apostasy?

The Spiritual War Behind the Science

Ephesians 6 reminds us that “we wrestle not against flesh and blood, but against principalities, against powers… against spiritual forces of wickedness in heavenly places” (Ephesians 6:12). Just as the Nephilim were not merely genetic anomalies, today’s bioengineering feats are not neutral, they are spiritually charged.

Satan has always sought to corrupt the image of God. In the garden, he tempted Eve with the promise that she could “be like God” (Genesis 3:5). In Genesis 6, he attempted to destroy the Messianic bloodline through hybridization. Now, in the modern age, he is inspiring a new generation of scientists to remake humanity in a counterfeit image.

Even mainstream bioethicists warn that humanity is venturing into dangerous territory. Once we cross the line of germline editing (modifying DNA in ways that pass on to future generations), we are engaging in permanent alterations of the human species.

This is not simply technological innovation—it is rebellion, a new form of genetic idolatry.

The Prophetic Implications

The book of Daniel says that in the Last Days, “knowledge will increase” (Daniel 12:4). Revelation describes a Beast system marked by global control, advanced image-making, and a mark that changes humanity’s destiny (Revelation 13:16–17).

Could the mark of the beast involve genetic manipulation? Some prophecy teachers speculate that it may include biometric or genetic encoding—something that alters not just one’s ability to buy or sell, but one’s very identity. If the Nephilim were irredeemable because they were no longer fully human, then it is possible that those who take the mark in the future could be permanently altered, disqualifying themselves from salvation (Revelation 14:9–11).

This fits with Satan’s strategy: to corrupt the image of God, replacing it with something hybridized, digitized, or mechanized. As in the days of Noah, humanity is being lured into a grand deception. A future where salvation is redefined and humanity is reengineered.

Redeeming the Narrative: A Call to Watch and Warn

Yet, we are not without hope. Jesus said, “When you see these things begin to happen, look up and lift up your heads, because your redemption is drawing near” (Luke 21:28). The rise of genetic manipulation is not only a sign of human arrogance—it is also a sign of prophetic acceleration. It tells us that the return of Christ is near.

As watchmen, we must sound the alarm. We must warn others that science without God becomes sorcery, that human enhancement without divine boundaries becomes rebellion, and that technology divorced from truth leads to deception.

We are called to resist the Nephilim spirit of this age—whether it comes in the form of fallen angels, genetic hybrids, or AI entities mimicking life. As Paul warned in 2 Thessalonians 2, a great deception is coming, one that will include lying signs and wonders. Our safeguard is the truth of God’s Word, our hope is in the return of Christ, and our strength is in the Holy Spirit.

Conclusion: Standing Firm in a Hybrid Age

The world is being prepared for a return to the days of Noah—where boundaries are erased, flesh is corrupted, and mankind is seduced by forbidden knowledge. We are not simply witnessing a scientific revolution. We are witnessing a spiritual reformation of evil.

The Nephilim of Genesis 6 were a warning. The words of Jesus in Matthew 24 are a reminder. And the prophecies of Revelation are a roadmap for what’s coming.

Let us watch. Let us warn. Let us hold fast to the truth in these final moments before the ark door closes again.

“As it was in the days of Noah, so it will be at the coming of the Son of Man.” — Matthew 24:37

RELATED:

TRANSHUMANISM: MARCHING TOWARD THE MARK

Bringing Transhumanism Down to Earth, Part 1: Military Intelligence Operations Cloaked in the False Promise of Transcendence

Transhumanism’s Assumptions and their ImplicationsGenetic Engineering: Scientists Edit DNA For First Time in Hopes To ‘Play God’

CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big

By Catalyst Capital

• Gene editing, also known as genome editing, allows scientists to modify the DNA of organisms using biotechnological techniques.
• CRISPR-Cas9 is the most widely used gene editing technology, known for its simplicity and versatility.
• Major publicly traded CRISPR companies include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Beam Therapeutics, Caribou Biosciences, and Prime Medicine.

Gene editing, also known as genome editing, is a method where the DNA of an organism is modified using biotechnological techniques. It allows scientists to add, remove, or alter genetic material at particular locations in the genome.

This 2-part series will cover the basics of CRISPR-Cas9 (see below) in part 1 and the major players involved and how to differentiate the companies competing in this space in part 2. I think it is an important time to learn about this technology now that we are on the cusp of the first approval in the space and are potentially coming out of what was a terrible 3 year bear market for biotechs.

CRISPR-Cas9: The most widely used and recognized gene editing technology is CRISPR-Cas9. It was developed into a genome editing tool by Emmanuelle Charpentier and Jennifer Doudna, who were awarded the 2020 Nobel Prize in Chemistry for their work. Feng Zhang and George Church also made significant contributions to its development for use in eukaryotic cells (like human cells).

CRISPR-Cas9 is a revolutionary gene-editing tool that many regard as transformational because of its simplicity and versatility. Many experts think it has the potential to completely revolutionize human health.

Here’s a quick overview of how it works:

CRISPR-Cas9 Basic Parts

1. CRISPR Sequence: Originally part of the bacterial immune system, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) sequences are segments of DNA containing short repetitions of base sequences.
2. Cas9: An enzyme that acts like a pair of molecular scissors. It can cut DNA at a specific location.
3. Guide RNA (gRNA): A piece of RNA that is designed to be complementary to the target DNA sequence. It “guides” the Cas9 to the right part of the genome.

CRISPR-Cas9 Process

Designing the Guide RNA: Researchers design a gRNA that matches the sequence of the DNA they want to edit.

Designing a gRNA for CRISPR-Cas9 gene editing involves a precise process to ensure specificity and efficiency in targeting the desired DNA sequence. Here’s an overview of how researchers design a gRNA:

Identifying the Target Sequence

Target Selection: Researchers first identify the specific sequence in the DNA that they want to edit.

Identifying the specific DNA sequence to edit using CRISPR-Cas9 or any other gene editing tool involves a combination of scientific knowledge, research, and bioinformatics tools.

Often, the desire to edit a specific DNA sequence stems from prior research. For instance, scientists might target a gene known to cause a disease or a genetic pathway influencing a particular trait.

Researchers review scientific literature to understand the function of genes and their associated sequences, relying heavily on databases like GenBank, the UCSC Genome Browser, and the ENSEMBL database which provide comprehensive genomic information for various organisms.

Advancements in computing power with tools like machine learning and artificial intelligence is helping speed up the research process. Software tools can analyze genetic sequences to identify genes and analyze prior clinical trials to determine target areas and chances of success faster and more accurately than ever before.

The target sequence should be unique to the region of interest to minimize off-target effects, where the CRISPR system edits unintended parts of the genome.

A burgeoning field of analytics has sprouted up to assist in determining off target edits. The nemesis of CRISPR-Cas9 and the entire gene editing field is off target edits. Regulators like the FDA in the USA are keenly focused on off target edits when evaluating the risk-reward of gene editing trials underway.

Documents published Friday revealed the agency plans to focus a meeting of expert advisers next week on this risk, known as “off-target” edits, and on whether there’s enough evidence to show it’s not a safety concern.

PAM Sequence Requirement: They must also consider the presence of a PAM (Protospacer Adjacent Motif) sequence near the target site. Cas9 requires a short, specific DNA sequence right next to the target site for binding and cutting. The PAM sequence is essential for Cas9 binding and cleavage.

Designing the gRNA Sequence

• Complementary Design: The gRNA is designed to be complementary to the target DNA sequence, allowing it to bind specifically to that sequence. Typically, about 20 nucleotides of the gRNA are designed to be complementary to the target site. A nucleotide is the basic structural unit and building block of DNA and RNA – they consist of 3 components (nitrogenous base, sugar molecule, and phosphate group) and their role is to store the genetic information of an organism.
• Avoiding Off-Target Effects: As I mentioned before, it’s crucial to ensure that the gRNA is specific to the target sequence and does not bind to other similar sequences in the genome, which can lead to off-target edits. Analytical tools are used to analyze the potential off-target sites.

Using Bioinformatics Tools

• Software Assistance: Researchers use various software and online tools to design gRNA sequences. These tools help in identifying the most efficient and specific gRNA sequences, taking into account factors like the efficiency of targeting, potential off-target sites, and the presence of the PAM sequence.
• Optimization: The tools also assist in optimizing the gRNA for various factors like GC content, which can affect the stability and effectiveness of the gRNA.

Synthesizing the gRNA

• Once the sequence is designed, the gRNA is synthesized. This can be done chemically, or the gRNA can be transcribed in vitro or in cells from a DNA template.

Testing and Validation

• After synthesis, the gRNA is tested in cells or in vitro to ensure it effectively targets the desired DNA sequence. This involves checking for the intended edits and assessing any potential off-target effects.

1. Formation of the CRISPR-Cas9 Complex: The gRNA binds to the Cas9 enzyme, forming a complex.
2. Targeting the DNA: The gRNA within this complex guides Cas9 to the target DNA sequence in the genome by base pairing with the complementary DNA sequence.
3. Cutting the DNA: Once the CRISPR-Cas9 complex locates and binds to the target DNA sequence, Cas9 cuts the DNA at this precise location. This cut typically happens in both strands of the DNA helix, creating a double-strand break (DSB).
4. DNA Repair and Editing: After the DNA is cut, the cell’s natural repair mechanisms kick in. There are two main pathways for repair:
   • Non-Homologous End Joining (NHEJ): This pathway often introduces insertions or deletions (indels) at the cut site, which can disrupt the gene, effectively “knocking out” its function.
   • Homology-Directed Repair (HDR): If a DNA template with a desired sequence is provided, the cell can use this template to repair the cut, incorporating the new sequence into the genome. This allows for precise gene editing, such as correcting a mutation.

5. Experimental Validation

• In Silico Analysis: Before actual experiments, in silico (computer-based) analysis predicts the effectiveness and specificity of the target site.
• Laboratory Testing: Initial experiments in cell cultures or model organisms help validate the target site’s effectiveness and safety.

CRISPR Applications in Human Health

The application of CRISPR in human health is creating treatments for genetic disorders by correcting genetic defects. Just like a computer program with faulty coding, a human with a faulty genetic code can now be edited. the advantage is CRISPR has high precision, is relatively easy to design and implement, and is adaptable to many different organisms.

The challenge for CRISPR is there are genuine ethical concerns, particularly regarding human germline editing. This is editing done to a human that can be passed on to subsequent generations. Any genetic changes made in these germline cells will be passed on to all cells of the resulting organism, including its own germline cells. This means the changes can be inherited by the organism’s offspring.

There are also potential off-target effects (unintended edits in the genome); and the efficiency and precision of the editing process is still be sussed out.

Who are the Major CRISPR Companies that are Publicly Traded?

In part 2, we will discuss the major players in CRISPR that you can invest in right now and differentiate amongst them. But for now, these are the major CRISPR companies that are publicly traded:

1. CRISPR Therapeutics (CRSP): co-founded by one of the pioneers of CRISPR-Cas9, Emmanuelle Charpentier. It focuses on developing gene-based medicines for serious diseases. CRISPR is on the cusp of potentially having the first FDA approved therapy using gene editing, CASGEVY (exa-cel) – the FDA rules on this on December 8, 2023. CRSP has roughly $1.4B in net cash vs annual cash burn of $350 Million so it sits in a good position as it waits for its first drug to be approved. CRSP also will get $200M from its partner Vertex Pharmaceuticals (VRTX) if/when exa-cel is approved. CRSP stands to receive 40% of revenues from VRTX if their drug is approved.
2. Editas Medicine (EDIT): This company is engaged in discovering and developing genome editing therapies. It works on treating patients with genetically defined diseases by correcting their disease-causing genes.
3. Intellia Therapeutics (NTLA): Intellia is known for its work in developing in vivo (inside the body) gene editing treatments. It aims to use CRISPR-Cas9 technology to treat various diseases, including rare genetic conditions.
4. Beam Therapeutics (BEAM): Beam Therapeutics stands out for its focus on base editing, a more precise form of CRISPR editing that allows for single base pair changes without creating double-strand breaks in DNA.
5. Caribou Biosciences (CRBU): Co-founded by Jennifer Doudna, a CRISPR-Cas9 co-inventor, Caribou Biosciences focuses on CRISPR genome editing technology to develop cellular immunotherapies for various diseases, including cancer.
6. Prime Medicine (PRME): Prime Medicine’s approach represents an advancement in the field of gene editing, particularly in providing solutions for a wide spectrum of diseases through precise genetic modifications. Their work in Prime Editing holds promise for addressing genetic conditions that were previously challenging to treat.

I hope this covers the basics of CRISPR-Cas9 and gene editing. This revolutionary tool has the potential to disrupt health care and make a lot of wealth for investors that choose the correct companies to invest in.